GlassScriptPhysician profile
James R Gavin
$1,437,090.60
in general payments reported to CMS, 2019-2025
16 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594K · 2020: $574K · 2021: $133K · 2022: $9,047 · 2023: $39K · 2024: $66K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85K · Consulting Fee: $29K · Travel and Lodging: $7,764 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,000 · Food and Beverage: $1,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $84,668.75 |
| Consulting Fee | $29,337.00 |
| Travel and Lodging | $7,764.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,000.00 |
| Food and Beverage | $1,246.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $742,699.61 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $139,324.84 | 2019-2020 | |
| Novo Nordisk INC | $122,896.12 | 2019-2025 | |
| Lilly USA, LLC | $118,125.37 | 2019-2025 | Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $100,645.21 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89,129.81 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $54,764.81 | 2019-2021 | |
| Abbott Laboratories | $25,693.27 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Embecta Corp. | $18,742.50 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12,828.78 | 2019-2020 | |
| Eli Lilly and Company | $6,300.00 | 2023-2024 | Jardiance |
| Boehringer Ingelheim Rcv Gmbh & Co Kg | $2,120.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $2,000.00 | 2021 | |
| Medtronic Minimed, INC. | $1,650.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.34 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.